Phase 3 Epilepsy Trial, Recruiting NCT07594158 Sponsor: Ono Pharmaceutical Co., Ltd. Condition: Epilepsy
Back to Epilepsy

Phase 3 Epilepsy Trial, Recruiting

NCT07594158
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a Japanese male or female patient between 2 and 17 years old at the time of agreeing to join the trial
  • You have been diagnosed with epilepsy with a specific type of seizure (called focal onset seizures) that has not been fully controlled by medication for at least 6 months before joining
  • You have had at least one of these seizures in the 4 weeks before signing up, based on records such as a seizure diary
  • You have been taking between 1 and 3 anti-seizure medications at steady, unchanged doses for at least 2 months before joining

Who may not be able to join:

  • You have had a severe, prolonged seizure episode that required a hospital stay within the 3 months before joining
  • You have a history of seizures that are caused by psychological factors rather than epilepsy
  • Your seizures are a specific type that only affect sensation or thought without any physical movement, or you have a type of epilepsy that starts in a generalised way from the beginning
  • You have been diagnosed with a specific severe form of epilepsy called Lennox-Gastaut syndrome
  • You have a history of a serious allergic skin reaction to a medication, such as Stevens-Johnson syndrome or a similar severe drug reaction, that required a hospital stay (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Project Leader, Ono PharmaceuticalCo., Ltd.

Phone: +18665877745 (Toll-Free)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Ono Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
30 May 2026
Est. completion
30 March 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Adverse events and adverse drug reactions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov